Analysis

Pharma Technology Focus – Issue 57

Pharma Technology Focus – Issue 57

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

Takeda turns its focus overseas

Takeda turns its focus overseas

Is US drug manufacturing homeward bound?

Is US drug manufacturing homeward bound?

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Therapeutic orphans: child-friendly drugs and the quest for adherence

Therapeutic orphans: child-friendly drugs and the quest for adherence

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

The Hive: new incubator makes a beeline for non-traditional pharma companies

The Hive: new incubator makes a beeline for non-traditional pharma companies

Tackling false trial data in China

Tackling false trial data in China

Pfizer’s big antibiotic buyout: a sign of things to come?

Pfizer’s big antibiotic buyout: a sign of things to come?

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Bringing together Oxford and Cambridge’s biopharma clusters

Bringing together Oxford and Cambridge’s biopharma clusters

IBM’s lab on a chip breakthrough seeks out cancers origin

IBM’s lab on a chip breakthrough seeks out cancers origin

US Precision Medicine Initiative gears up for a massive e-health drive

US Precision Medicine Initiative gears up for a massive e-health drive

Going global: India’s big biosimilar move

Going global: India’s big biosimilar move

Is the stage set for global drug price regulation?

Is the stage set for global drug price regulation?

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50

Xilonix: new anti-tumour cancer drug is on the fast-track

Xilonix: new anti-tumour cancer drug is on the fast-track

ChemoFilter: getting the drugs back out

ChemoFilter: getting the drugs back out

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results
cachename:Featurescachekey:rd-137342983_-954009584_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_971827490